Skip to content

Study · Observational study · n = 27,204 · 2021

4 results

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.

Thomsen RW, Knudsen JS, Kahlert J, Baggesen LM, Lajer M, Holmgaard PH, Vedin O, Ustyugova A, Sørensen HT

Journal of the American Heart Association25 May 2021Cited by 25 (Europe PMC)

PMID34032121 (opens in a new tab)PMCIDPMC8483550 (opens in a new tab)DOI10.1161/jaha.120.019356 (opens in a new tab)PepBankPUB-34032121
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Danish adults with type 2 diabetes, new users of liraglutide had a rate of expanded MACE similar to new users of empagliflozin.

    In plain wordsIn Danish adults with type 2 diabetes, liraglutide users and empagliflozin users had similar rates of major heart events.

    Peptide
    Liraglutide
    Outcome
    No significant changeExpanded major adverse cardiac events
    Study

    n = 27,204

    Comparator
    Empagliflozin
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    aHR on-treatment
    1.02 ratio
    empagliflozin vs liraglutide
    aHR intention-to-treat
    1.06 ratio
    empagliflozin vs liraglutide

    Source sentences

    Summary
    empagliflozin versus liraglutide was associated with a similar rate of expanded major adverse cardiac events (OT aHR, 1.02; 95% CI, 0.91-1.14; ITT aHR, 1.06; 95% CI, 0.96-1.17)
    1 context sentence
    Summary · context
    For the present study, we included 14 498 new users of empagliflozin and 12 706 new users of liraglutide, 2015 to 2018.
  2. 02HumanObservational studyEfficacy outcome

    In Danish adults with type 2 diabetes, new users of liraglutide had a rate of heart failure hospitalization or all-cause death similar to new users of empagliflozin.

    In plain wordsIn Danish adults with type 2 diabetes, liraglutide users and empagliflozin users had similar rates of heart failure hospital stays or death.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeart failure hospitalization or all-cause death
    Study

    n = 27,204

    Comparator
    Empagliflozin
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    aHR on-treatment
    0.97 ratio
    empagliflozin vs liraglutide
    aHR intention-to-treat
    1.02 ratio
    empagliflozin vs liraglutide

    Source sentences

    Summary
    and HHF or all-cause death (OT aHR, 0.97; 95% CI, 0.85-1.11; ITT aHR, 1.02; 95% CI, 0.91-1.14)
    1 context sentence
    Summary · context
    For the present study, we included 14 498 new users of empagliflozin and 12 706 new users of liraglutide, 2015 to 2018.
  3. 03HumanObservational studyEfficacy outcome

    In Danish adults with type 2 diabetes, new users of liraglutide had a higher rate of a first heart failure hospitalization or loop-diuretic initiation than new users of empagliflozin.

    In plain wordsIn Danish adults with type 2 diabetes, liraglutide users had more first heart failure hospital stays or water-pill starts than empagliflozin users.

    Peptide
    Liraglutide
    Outcome
    IncreaseFirst heart failure hospitalization or loop-diuretic initiation
    Study

    n = 27,204

    Comparator
    Empagliflozin
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    aHR on-treatment
    0.8 ratio
    empagliflozin vs liraglutide
    aHR intention-to-treat
    0.87 ratio
    empagliflozin vs liraglutide

    Source sentences

    Summary
    a decreased rate of a first incident HHF or loop-diuretic initiation (OT aHR, 0.80; 95% CI, 0.68-0.94; ITT aHR, 0.87; 95% CI, 0.76-1.00)
    1 context sentence
    Summary · context
    For the present study, we included 14 498 new users of empagliflozin and 12 706 new users of liraglutide, 2015 to 2018.
  4. 04HumanObservational studyEfficacy outcome

    In Danish adults with type 2 diabetes, new users of liraglutide had a higher rate of all-cause hospitalization or death than new users of empagliflozin.

    In plain wordsIn Danish adults with type 2 diabetes, liraglutide users had more hospital stays or deaths from any cause than empagliflozin users.

    Peptide
    Liraglutide
    Outcome
    IncreaseAll-cause hospitalization or death
    Study

    n = 27,204

    Comparator
    Empagliflozin
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    aHR on-treatment
    0.93 ratio
    empagliflozin vs liraglutide
    aHR intention-to-treat
    0.93 ratio
    empagliflozin vs liraglutide

    Source sentences

    Summary
    and of all-cause hospitalization or death (OT aHR, 0.93; 95% CI, 0.89-0.98; ITT aHR, 0.93; 95% CI, 0.90-0.97)
    1 context sentence
    Summary · context
    For the present study, we included 14 498 new users of empagliflozin and 12 706 new users of liraglutide, 2015 to 2018.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.